Clopidogrel NVP-BVU972 and aspirin with warfarin aspirin Ares clopidogrel to aspirin alone. The results show that warfarin superior to the combination of aspirin, clopidogrel in Pr Vascular prevention Rer events without erh Increase the incidence of major bleeding. It also prevents the use of clopidogrel associated with aspirin more thromboembolic events than aspirin alone, but at the expense of a significant increase in major bleeding, and with a tendency to be increased Mortality hter t. As clopidogrel plus aspirin reduces the risk of serious vascular Ren events, this combination is indicated when treatment with warfarin is difficult because the patients are monitored or controlled, if refuse You k Can not be carried out or are unreliable, precious metals,.
In this respect, the M Possibility of resistance to clopidogrel and / or aspirin are NVP-BVU972 1185763-69-2 investigated. In the study, Averroes, was apixaban, an oral direct inhibitor of activated factor X in doses of 5 mg twice t Possible as compared to aspirin. In this study, apixaban to 5600 patients with atrial fibrillation who had a relatively low risk and could not receive medical care, which administered with warfarin. Apixaban was compared with aspirin 81-324 mg / day. The study was stopped more than tt is expected because of the advantage in patients with apixaban. Reduction of isch Mixed stroke was statistically significantly without serious bleeding complications and a slight increase in minor bleeding, warfarin, and the new Table 2 shows some oral anticoagulant pharmacodynamic properties of new compounds for antithrombotic warfarin compared.
The new drug that dabigatran has been approved for use in the AF mode. Other drugs are in Phase III trials. Comparing tests with new agents and warfarin on the basis of the criterion for non-inferiority, showed a significant effect in preventing thromboembolic complications in patients following orthopedic Indian intervention. Are these new anticoagulants have a real impact on the Pr Prevention of thromboembolism, especially stroke, in patients with atrial fibrillation The comparative studies presented in the following sections, the advantages and disadvantages compared to warfarin are discussed. Dabigatran etexilate is a prodrug, the active principle dabigatran effects of specific inhibitors of thrombin is both free and bound to fibrin.
In the RE-LY dabigatran was administered in two doses: 150 mg or 110 mg twice t possible. Results on the criterion for non-inferiority of the base show that the dose of 150mg twice t Was possible significantly more effective than warfarin in the Press Prevention ish Endemic stroke with Hnlichen H FREQUENCY of h Hemorrhagic stroke. The dosage of 110 mg twice t Was possible Similar to warfarin in preventing thromboembolism and pr Presents with less bleeding. Patients with a dose of 150 mg twice t Resembled treated had a 35% reduction in the risk of systemic embolism and 74% for h Hemorrhagic stroke. These numbers are impressive. Can describe the NNT the results from the viewpoint of t Aligned medical practice. Although the differences between dabigatran and warfarin are some of the important results and refer to the number of patients, the NNT endpoints are not convincing and fill the 35% reduction of Schlaganf Not seem as impressive. The results of the Phase IV studies provide more data on safety and efficiency. Be considered as side effects, it is perhaps premature to rdern f-feeding. For example, the endpoints are not taken into account m